Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
By J. Flores-Montero, L. Sanoja-Flores, B. Paiva, N. Puig, O. García-Sánchez, S. Böttcher, V. V. D. Velden, J. Perez-Moran, M. Vidriales, R. García-Sanz and 23 more. Leukemia, 2017
605 citations recorded by the source corpus.
Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after therapy. However, current flow-MRD has lower sensitivity than molecular methods and lacks standardization. Here we report on a novel next generation flow (NGF) approach for highly sensitive and standardized MRD detection in MM. An optimized 2-tube 8-color antibody panel was constructed in five cycles of design-evaluation-redesign. In addition, a bulk-lysis procedure was established for acquisition of ⩾107 cells/sample, and novel software tools were constructed for automatic plasma cell gating. Multicenter evaluation of 110 follow-up BM from MM patients in very good partial response (VGPR) or CR showed a higher sensitivity for NGF-MRD vs conventional 8-color flow-MRD -MRD-positive rate of 47 vs 34% (P=0.003)-. Thus, 25% of patients classified as MRD-negative by conventional 8-color flow were MRD-positive by NGF, translating into a significantly longer progression-free survival for MRD-negative vs MRD-positive CR patients by NGF (75% progression-free survival not reached vs 7 months; P=0.02). This study establishes EuroFlow-based NGF as a highly sensitive, fully standardized approach for MRD detection in MM which overcomes the major limitations of conventional flow-MRD methods and is ready for implementation in routine diagnostics.
Subfields: Genetics, Hematology, Oncology
View Paper: https://www.semanticscholar.org/paper/653029030410a2c0aa9dca41316a0a8dadad1ffc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Adam D. Cohen
- E. Stadtmauer
- A. Garfall
- J. Melenhorst
- S. Lacey
- E. Lancaster
- M. Davis
- D. Vogl
Citations in the corpus
- B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. (2019, methodology): “from the EuroFlow protocol (39) as described in Supplemental”